Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.
Journal
Clinical drug investigation
ISSN: 1179-1918
Titre abrégé: Clin Drug Investig
Pays: New Zealand
ID NLM: 9504817
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
accepted:
02
11
2021
pubmed:
26
11
2021
medline:
15
1
2022
entrez:
25
11
2021
Statut:
ppublish
Résumé
Ciltacabtagene autoleucel (cilta-cel) is a novel agent being investigated in the single-arm CARTITUDE-1 trial (NCT03548207) for patients with relapsed or refractory multiple myeloma who are triple-class exposed to an immunomodulatory drug, proteasome inhibitor, and an anti-CD38 monoclonal antibody. The objective of this study was to evaluate the comparative efficacy of cilta-cel vs physician's choice of treatment, as no head-to-head trials have been conducted. An external control arm for CARTITUDE-1 was created from patients in the long-term follow-up for three clinical trials of daratumumab (POLLUX, CASTOR, and EQUULEUS) who satisfied the eligibility criteria of CARTITUDE-1. These patients received physician's choice of treatment following the discontinuation of study drugs. Inverse probability of treatment weighting was used to align the external control and CARTITUDE-1 populations on important baseline characteristics. Overall response rate, complete response or better rate, progression-free survival, time to next treatment, and overall survival were assessed. Several sensitivity analyses were conducted. After propensity score weighting, baseline characteristics were comparable between cohorts. Patients showed improved results with cilta-cel vs physician's choice of treatment: overall response rate (relative risk: 2.95 [95% confidence interval (CI) 2.27, 3.84; p < 0.0001]), complete response or better (relative risk: 111.70 [95% CI 29.08, 429.06; p < 0.0001]), progression-free survival (hazard ratio [HR]: 0.24 [95% CI 0.15, 0.37; p < 0.0001]), time to next treatment (HR: 0.14 [95% CI 0.09, 0.22; p < 0.0001]), and overall survival (HR: 0.21 [95% CI 0.13, 0.35; p < 0.0001]). Results were consistent across all sensitivity analyses. Cilta-cel showed superior efficacy compared with physician's choice of treatment, making it a promising new treatment option for patients with triple-class exposed relapsed or refractory multiple myeloma.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
Ciltacabtagene autoleucel (cilta-cel) is a novel agent being investigated in the single-arm CARTITUDE-1 trial (NCT03548207) for patients with relapsed or refractory multiple myeloma who are triple-class exposed to an immunomodulatory drug, proteasome inhibitor, and an anti-CD38 monoclonal antibody. The objective of this study was to evaluate the comparative efficacy of cilta-cel vs physician's choice of treatment, as no head-to-head trials have been conducted.
METHODS
METHODS
An external control arm for CARTITUDE-1 was created from patients in the long-term follow-up for three clinical trials of daratumumab (POLLUX, CASTOR, and EQUULEUS) who satisfied the eligibility criteria of CARTITUDE-1. These patients received physician's choice of treatment following the discontinuation of study drugs. Inverse probability of treatment weighting was used to align the external control and CARTITUDE-1 populations on important baseline characteristics. Overall response rate, complete response or better rate, progression-free survival, time to next treatment, and overall survival were assessed. Several sensitivity analyses were conducted.
RESULTS
RESULTS
After propensity score weighting, baseline characteristics were comparable between cohorts. Patients showed improved results with cilta-cel vs physician's choice of treatment: overall response rate (relative risk: 2.95 [95% confidence interval (CI) 2.27, 3.84; p < 0.0001]), complete response or better (relative risk: 111.70 [95% CI 29.08, 429.06; p < 0.0001]), progression-free survival (hazard ratio [HR]: 0.24 [95% CI 0.15, 0.37; p < 0.0001]), time to next treatment (HR: 0.14 [95% CI 0.09, 0.22; p < 0.0001]), and overall survival (HR: 0.21 [95% CI 0.13, 0.35; p < 0.0001]). Results were consistent across all sensitivity analyses.
CONCLUSIONS
CONCLUSIONS
Cilta-cel showed superior efficacy compared with physician's choice of treatment, making it a promising new treatment option for patients with triple-class exposed relapsed or refractory multiple myeloma.
Identifiants
pubmed: 34822128
doi: 10.1007/s40261-021-01100-y
pii: 10.1007/s40261-021-01100-y
pmc: PMC8755696
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
29-41Informations de copyright
© 2021. The Author(s).
Références
Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548–67. https://doi.org/10.1002/ajh.25791 .
doi: 10.1002/ajh.25791
pubmed: 32212178
Dimopoulos MA, Richardson PG, Moreau P, Anderson KC. Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat Rev Clin Oncol. 2015;12(1):42–54.
doi: 10.1038/nrclinonc.2014.200
Weisel KC, Martin T, Yong K, Qi K, Londhe A, Kobos R, et al. Characteristics and treatment patterns of triple-class exposed patients with relapsed/refractory multiple myeloma who participated in clinical trials of daratumumab [O127]. In: The 47th annual meeting of the european society of blood and marrow transplantation: physicians - oral sessions (O010-O169). Bone Marrow Transplant. 2021;56:137–8.
Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266–75. https://doi.org/10.1038/s41375-019-0435-7 .
doi: 10.1038/s41375-019-0435-7
pubmed: 30858549
pmcid: 6820050
Mehra M, Vogel M, Valluri S, Nair S, Schecter J, Slowik R, et al. Patient characteristics, treatment patterns and outcomes in patients with triple class refractory multiple myeloma [E-poster #1032]. In: 25th European Hematology Association (EHA) annual congress (Virtual). 11–14 Jun 2020. https://library.ehaweb.org/eha/2020/eha25th/293522 . Accessed 1 Sept 2021.
Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a BCMA-directed CAR T-cell therapy in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314–324.
doi: 10.1016/S0140-6736(21)00933-8
Usmani SZ, Berdeja JG, Madduri D, Jakubowiak AJ, Agha ME, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): updated results from CARTITUDE-1 [oral presentation]. In: 2021 ASCO Annual Meeting I. J Clin Oncol. 2021;39(15_suppl):8005.
Legend Biotech. U.S. Food and Drug Administration grants BCMA CAR-T cilta-cel priority review for the treatment for relapsed/refractory multiple myeloma [press release]. https://www.legendbiotech.com/pdf/LEGN_PR_05262021.pdf . Accessed 28 May 2021.
Janssen. Janssen announces CAR-T therapy ciltacabtagene autoleucel (cilta-cel) accepted for accelerated assessment in Europe for the treatment of patients with heavily pretreated multiple myeloma [press release]. https://johnsonandjohnson.gcs-web.com/static-files/315911e1-8c26-4933-9707-295fc794bbdb . Accessed 12 Apr 2021.
ClinicalTrials.gov. A study comparing daratumumab, lenalidomide, and dexamethasone with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma. https://clinicaltrials.gov/ct2/show/NCT02076009 . Accessed 13 Jul 2021.
ClinicalTrials.gov. Addition of daratumumab to combination of bortezomib and dexamethasone in participants with relapsed or refractory multiple myeloma. https://clinicaltrials.gov/ct2/show/NCT02136134 . Accessed 13 Jul 2021.
ClinicalTrials.gov. A study of JNJ-54767414 (HuMax CD38) (anti-CD38 monoclonal antibody) in combination with backbone treatments for the treatment of patients with multiple myeloma. https://clinicaltrials.gov/ct2/show/NCT01998971 . Accessed 13 Jul 2021.
Li F, Morgan KL, Zaslavsky AM. Balancing covariates via propensity score weighting. J Am Stat Assoc. 2018;113(521):390–400.
doi: 10.1080/01621459.2016.1260466
Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319–31.
doi: 10.1056/NEJMoa1607751
Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754–66.
doi: 10.1056/NEJMoa1606038
Chari A, Suvannasankha A, Fay JW, Arnulf B, Kaufman JL, Ifthikharuddin JJ, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. 2017;130(8):974–81.
doi: 10.1182/blood-2017-05-785246
Hernán MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183(8):758–64.
doi: 10.1093/aje/kwv254
Backenroth D. How to choose a time zero for patients in external control arms. Pharm Stat. 2021;20(4):783–92.
doi: 10.1002/pst.2107
Berger VW, Sankoh A. Prognostic variables in clinical trials. Wiley StatsRef Stat Ref Online. 2014. https://doi.org/10.1002/9781118445112.stat07072 .
doi: 10.1002/9781118445112.stat07072
Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083–107.
doi: 10.1002/sim.3697
Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–46.
doi: 10.1016/S1470-2045(16)30206-6
Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Mak. 2018;38(2):200–11.
doi: 10.1177/0272989X17725740
Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submission to NICE. http://nicedsu.org.uk/wp-content/uploads/2017/05/Population-adjustment-TSD-FINAL.pdf . Accessed 29 Oct 2021.
Lee J, Chia K. Estimation of prevalence rate ratios for cross sectional data: an example in occupational epidemiology. BR J Ind Med. 1993;50(9):861.
pubmed: 8398881
pmcid: 1061320
Funk MJ, Westreich D, Wiesen C, Stürmer T, Brookhart MA, Davidian M. Doubly robust estimation of causal effects. Am J Epidemiol. 2011;173(7):761–7.
doi: 10.1093/aje/kwq439
Kumar S, Durie B, Nahi H, Vij R, Dimopoulos MA, Kastritis E, et al. Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma. Leuk Lymphoma. 2019;60(1):163–71.
doi: 10.1080/10428194.2018.1459609
Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver N, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: a propensity score analysis. Cancer. 2019;125(15):2579–86.
pubmed: 30985931
Chin CK, Lim K, Lewis K, Jain P, Qing Y, Feng L, et al. Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multi-centre propensity-score-matched study. Br J Haematol. 2020;191(5):806–15.
doi: 10.1111/bjh.17072
Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21(2):207–21.
doi: 10.1016/S1470-2045(19)30788-0
Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A et al. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. Cancer. 2021;127(22):4198–12.
doi: 10.1002/cncr.33809
Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381(8):727–38.
doi: 10.1056/NEJMoa1903455
Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–16.
doi: 10.1056/NEJMoa2024850
Ma X, Long L, Moon S, Adamson BJ, Baxi SS. Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR. medRxiv. 2020. https://doi.org/10.1101/2020.03.16.20037143 .
doi: 10.1101/2020.03.16.20037143
pubmed: 33330879
pmcid: 7743088
Mateos M-V, Weisel K, Stefano VD, Perrot A, Donk NWCJvd, Goldschmidt H, et al. A prospective, non-interventional, multinational study of real-life standard of care in patients with relapsed/refractory multiple myeloma with ≥ 3 prior lines of therapy: interim data from LocoMMotion [E-poster #987]. In: European Hematology Association (EHA) Annual Congress (Virtual). 2021 Jun 9–17. https://library.ehaweb.org/eha/2021/eha2021-virtual-congress/325745 . Accessed 1 Sept 2021.
Caers J, Paiva B, Zamagni E, Leleu X, Bladé J, Kristinsson S, et al. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. J Hematol Oncol. 2018;11(1):10.
doi: 10.1186/s13045-017-0549-1